<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Calcitonin in the prevention and treatment of osteoporosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Calcitonin in the prevention and treatment of osteoporosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Calcitonin in the prevention and treatment of osteoporosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Harold N Rosen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Clifford J Rosen, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kenneth E Schmader, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 06, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Osteoporosis is a disorder of bone characterized by reduced mineral density and bone mass (see
         <a class="medical medical_review" href="/z/d/html/2044.html" rel="external">
          "Pathogenesis of osteoporosis"
         </a>
         ). Multiple therapeutic regimens have been designed to prevent and treat osteoporosis in adults by inhibiting bone resorption and/or increasing bone formation. The efficacy of
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         in the prevention and treatment of osteoporosis will be reviewed here. We do not use calcitonin as first-line therapy, because more effective drugs are available for prevention of bone loss and reduction of fracture risk. (See
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3436690751">
         <span class="h1">
          CONCERNS ABOUT THE USE OF CALCITONIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          Calcitonin
         </a>
         is a peptide composed of 32 amino acids that binds to osteoclasts and inhibits bone resorption [
         <a href="#rid1">
          1,2
         </a>
         ]. The main concern about treatment with calcitonin, however, is that more effective drugs (eg, bisphosphonates) are available for the prevention of bone loss and reduction of fracture risk [
         <a href="#rid3">
          3-5
         </a>
         ]. For this reason, we typically do not use calcitonin to treat osteoporosis, unless pain from an acute osteoporotic fracture is a problem. In this setting, calcitonin could be used in the short term (until the pain has abated), and then the patient should be switched to an osteoporosis therapy that more effectively prevents subsequent fracture. (See
         <a class="medical medical_review" href="/z/d/html/7775.html" rel="external">
          "Osteoporotic thoracolumbar vertebral compression fractures: Clinical manifestations and treatment", section on 'Calcitonin'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">
          "Bisphosphonate therapy for the treatment of osteoporosis"
         </a>
         .)
        </p>
        <p>
         Another concern is that the long-term use of
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         for osteoporosis has been associated with an increase in cancer rates [
         <a href="#rid6">
          6
         </a>
         ]. The European Medicines Agency (EMA) reviewed data provided by the companies who manufacture calcitonin-containing medications, postmarketing safety data, and randomized trials, and it reported that a higher proportion of patients treated with calcitonin-containing medications for long periods of time developed cancer (various types including basal cell carcinoma) than patients taking placebo [
         <a href="#rid6">
          6
         </a>
         ]. The increases in cancer rates were small and ranged from 0.7 to 2.4 percent for oral and nasal formulations, respectively. Because calcitonin is a weak osteoporosis drug and there are more effective drugs to prevent bone loss and fracture, the EMA concluded that the benefits of calcitonin do not outweigh the risks for the treatment of osteoporosis. However, the EMA has taken no formal action based on these concerns.
        </p>
        <p>
         A US Food and Drug Administration (FDA) advisory panel initiated an internal review of all
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         trials after a safety signal for prostate cancer was noted in clinical trials of oral calcitonin, a formulation under development. In a meta-analysis of 20 trials (17 nasal spray, 3 oral), the risk of malignancy was higher in the calcitonin-treated group (4.2 versus 2.9 percent with placebo, odds ratio [OR] 1.4, 95% CI 1.1-1.7) [
         <a href="#rid7">
          7
         </a>
         ]. The meta-analysis was limited by heterogeneity and by high dropout rates in some of the trials, making it difficult to establish direct causality. Nevertheless, the FDA advisory panel similarly concluded that the benefits of calcitonin do not outweigh its potential risks as an osteoporosis drug [
         <a href="#rid7">
          7
         </a>
         ]. If there is a need for calcitonin, its use should be limited to &lt;6 months.
        </p>
        <p>
         Other adverse effects of
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         include hypersensitivity reactions (bronchospasm, swelling of the tongue or throat, anaphylaxis), hypocalcemia, nasal adverse reactions (rhinitis, epistaxis), and the formation of antibodies to calcitonin [
         <a href="#rid8">
          8
         </a>
         ]. In clinical trials of nasal calcitonin in postmenopausal women, the most common adverse effects were rhinitis and epistaxis, occurring in 12 and 4 percent, respectively.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PREPARATIONS AND ROUTE OF ADMINISTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Calcitonins from many species are effective in humans, but salmon
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         is the one most widely used. It is highly potent in humans because of its high affinity (40 times that of human calcitonin) for the human calcitonin receptor and its slow rate of clearance [
         <a href="#rid1">
          1
         </a>
         ]. The only other calcitonin used clinically is human calcitonin, which is less potent but also less antigenic than salmon calcitonin. Most clinical trials of calcitonin have used salmon calcitonin, but human calcitonin is as effective [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          Calcitonin
         </a>
         is available in the United States for administration by the subcutaneous, intramuscular, and intranasal routes [
         <a href="#rid1">
          1,10-15
         </a>
         ]. The bioavailability of nasal salmon calcitonin is approximately 25 percent that of intramuscular calcitonin; thus, the biological effect of 50 international units of intramuscular salmon calcitonin is equivalent to that of 200 international units of nasal salmon calcitonin [
         <a href="#rid16">
          16
         </a>
         ]. There are also several other differences between the different preparations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The absorption of the nasal dose is delayed compared with the parenteral route [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The administration of salmon
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         is frequently associated with side effects such as nausea, vomiting, and flushing; these side effects are much less common with the nasal route [
         <a href="#rid1">
          1,17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasal salmon
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         may provide more effective analgesia than parenteral salmon calcitonin. (See
         <a class="local">
          'Bone pain'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Thus, the convenience and freedom from side effects make nasal salmon
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         the preferred route of administration in patients who can tolerate and cooperate with intranasal administration.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EFFICACY
         </span>
        </p>
        <p class="headingAnchor" id="H6679777">
         <span class="h2">
          Osteoporosis prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         The perimenopausal acceleration of bone loss is due to increased bone resorption. This has led to studies of the efficacy of
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         in preventing postmenopausal bone loss since it inhibits bone resorption. In one study, for example, 52 postmenopausal women were randomly assigned to treatment with either 100 international units nasal salmon calcitonin or placebo; all subjects received calcium supplementation. Over two years, mean spinal bone mineral density (BMD) increased by 2.5 percent in the calcitonin group and decreased by 5.7 percent in the placebo group (
         <a class="graphic graphic_figure graphicRef59085" href="/z/d/graphic/59085.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid11">
          11
         </a>
         ]. In comparison, whole body and forearm BMD did not differ between the placebo group and the calcitonin group. Other studies have shown similar results using both human [
         <a href="#rid9">
          9
         </a>
         ] and salmon [
         <a href="#rid12">
          12,18
         </a>
         ] calcitonin by both the subcutaneous and intranasal routes [
         <a href="#rid1">
          1
         </a>
         ]. In a two-year extension study of a randomized trial, nasal calcitonin maintained efficacy in preventing perimenopausal bone loss at the lumbar spine after as long as five years of continuous use (
         <a class="graphic graphic_figure graphicRef80875" href="/z/d/graphic/80875.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Osteoporosis treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          Calcitonin
         </a>
         may be effective in the treatment of established osteoporosis, but it is less effective than other available agents. In one study of calcitonin in osteoporosis, 208 older osteopenic women were treated with calcium and either intranasal placebo, 50, 100, or 200 international units of salmon calcitonin daily for two years. Mean spine BMD was increased by salmon calcitonin in a dose-dependent fashion, with a maximum effect at 200 international units daily. Salmon calcitonin was also associated with a significantly lower fracture rate than placebo [
         <a href="#rid13">
          13
         </a>
         ], a finding that has been confirmed by others (
         <a class="graphic graphic_figure graphicRef73907" href="/z/d/graphic/73907.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
         The largest trial of
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         for treatment of osteoporosis was a five-year trial in 1255 women with a lumbar spine T-score of &lt;-2 and at least one vertebral fracture who were randomly assigned to either placebo or 100, 200, or 400 international units of intranasal calcitonin per day (
         <a class="graphic graphic_figure graphicRef79619" href="/z/d/graphic/79619.html" rel="external">
          figure 4
         </a>
         ) [
         <a href="#rid20">
          20
         </a>
         ]. There was a small increase in spine BMD (1 to 1.5 percent) in all groups. The risk of vertebral fracture was significantly lower than placebo only in the group taking 200 international units per day, and the risk of nonvertebral fractures was significantly lower than placebo only in the group taking 100 international units per day. Thus, the beneficial effect of nasal calcitonin on vertebral BMD and vertebral fracture risk was small, inconsistent, and not dose dependent.
        </p>
        <p>
         Bone histology is normal in subjects with osteoporosis treated with
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         for two years [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         There are conflicting data on the effect of
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         on sites other than the spine. Two studies found that calcitonin had no beneficial effect outside the spine [
         <a href="#rid13">
          13,18
         </a>
         ], but other studies have shown improvement [
         <a href="#rid15">
          15,19,21-23
         </a>
         ]. The above studies were mostly conducted in postmenopausal women.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          Calcitonin
         </a>
         is less effective for the treatment of postmenopausal osteoporosis than bisphosphonates. As an example, in a placebo-controlled, randomized trial of
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         (10 mg per day) versus intranasal calcitonin (200 international units per day) for 12 months, BMD of the hip and spine increased significantly more in the alendronate group than in the calcitonin group [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Bone pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          Calcitonin
         </a>
         has a beneficial short-term effect on acute pain relief in patients who have sustained a vertebral fracture. The ability of calcitonin to relieve pain may represent a truly distinguishing feature from other drugs used in the treatment of osteoporosis. Why pain relief occurs is not well understood; one possibility is a rise in endorphin levels induced by calcitonin [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7775.html" rel="external">
          "Osteoporotic thoracolumbar vertebral compression fractures: Clinical manifestations and treatment", section on 'Calcitonin'
         </a>
         .)
        </p>
        <p>
         The ability of
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         to relieve pain is illustrated by the findings of a meta-analysis of 10 trials comparing calcitonin (nasal or parenteral) with placebo in patients with acute (onset &lt;10 days) or chronic (&gt;3 months) pain due to an osteoporotic compression fracture [
         <a href="#rid24">
          24
         </a>
         ]. After one week of treatment, there was a significant improvement in pain score at rest (three trials, 196 patients) and with activity (four trials, 228 patients) in patients receiving calcitonin for acute pain (mean difference for resting pain -3.39, 95% CI -4.02 to -2.76, using a visual analog scale from 0 to 10). There was also significant improvement in pain score two, three, and four weeks after starting treatment. In contrast, calcitonin was not effective for patients with chronic pain. The meta-analysis was limited by the small number of patients and heterogeneity of results. There were insufficient data to assess differences related to the route of calcitonin administration.
        </p>
        <p>
         The benefits of
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         on bone pain have been noted with use of either parental or nasal calcitonin [
         <a href="#rid25">
          25-28
         </a>
         ]. In one study, nasal calcitonin relieved pain more effectively than parenteral calcitonin (
         <a class="graphic graphic_figure graphicRef60350" href="/z/d/graphic/60350.html" rel="external">
          figure 5
         </a>
         ) [
         <a href="#rid26">
          26
         </a>
         ], but this observation needs confirmation.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Concern about the use of
         </strong>
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          calcitonin
         </a>
         <strong>
          for osteoporosis
         </strong>
         – We do
         <strong>
          not
         </strong>
         use calcitonin as first-line therapy for osteoporosis, because more effective drugs are available for prevention of bone loss and reduction of fracture risk, and there is some potential risk. (See
         <a class="local">
          'Concerns about the use of calcitonin'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">
          "Overview of the management of low bone mass and osteoporosis in postmenopausal women"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          Calcitonin
         </a>
         increases spine bone density and may decrease vertebral fracture risk. There are conflicting data on the effect of calcitonin on sites other than the spine. (See
         <a class="local">
          'Osteoporosis treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Short-term use to treat bone pain from acute vertebral fracture
         </strong>
         –
         <a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">
          Calcitonin
         </a>
         has a beneficial short-term effect on acute pain relief in patients who have sustained a vertebral fracture. In this setting, calcitonin could be used in the short term (until the pain has abated), and then the patient should be switched to an osteoporosis therapy that more effectively prevents subsequent fracture. (See
         <a class="local">
          'Bone pain'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2030.html" rel="external">
          "Bisphosphonate therapy for the treatment of osteoporosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7775.html" rel="external">
          "Osteoporotic thoracolumbar vertebral compression fractures: Clinical manifestations and treatment", section on 'Calcitonin'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Carstens JH Jr, Feinblatt JD. Future horizons for calcitonin: a U.S. perspective. Calcif Tissue Int 1991; 49 Suppl 2:S2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998; 338:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downs RW Jr, Bell NH, Ettinger MP, et al. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000; 85:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323:73.
          </a>
         </li>
         <li class="breakAll">
          European Medicines Agency recommends limiting long-term use of calcitonin medicines http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2012/07/human_pha_detail_000065.jsp&amp;mid=WC0b01ac058001d126 (Accessed on October 17, 2012).
         </li>
         <li class="breakAll">
          Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM341779.pdf (Accessed on March 06, 2013).
         </li>
         <li class="breakAll">
          http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021406s017s022lbl.pdf (Accessed on July 14, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacIntyre I, Stevenson JC, Whitehead MI, et al. Calcitonin for prevention of postmenopausal bone loss. Lancet 1988; 1:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reginster JY, Meurmans L, Deroisy R, et al. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. Eur J Clin Invest 1994; 24:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989; 299:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gennari C, Agnusdei D, Montagnani M, et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 1992; 50:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992; 305:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overgaard K, Hansen MA, Nielsen VA, et al. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Am J Med 1990; 89:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 1989; 30:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Overgaard K, Agnusdei D, Hansen MA, et al. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991; 72:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985; 3:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Civitelli R, Gonnelli S, Zacchei F, et al. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 1988; 82:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rico H, Revilla M, Hernández ER, et al. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study. Calcif Tissue Int 1995; 56:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109:267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gruber HE, Ivey JL, Baylink DJ, et al. Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 1984; 33:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sileghem A, Geusens P, Dequeker J. Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. Ann Rheum Dis 1992; 51:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzuoli GF, Passeri M, Gennari C, et al. Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 1986; 38:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knopp-Sihota JA, Newburn-Cook CV, Homik J, et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int 2012; 23:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyritis GP, Tsakalakos N, Magiasis B, et al. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int 1991; 49:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991; 49 Suppl 2:S9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyritis GP, Ioannidis GV, Karachalios T, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 1999; 15:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyritis GP, Paspati I, Karachalios T, et al. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 1997; 275:112.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2025 Version 17.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1933616" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Future horizons for calcitonin: a U.S. perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9494151" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Treatment of postmenopausal osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10843152" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1534476" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Treatment of postmenopausal osteoporosis with transdermal estrogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2113611" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2113611" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2113611" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2113611" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2895829" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Calcitonin for prevention of postmenopausal bone loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7982445" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2507027" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Effect of salcatonin given intranasally on early postmenopausal bone loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1571851" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1393035" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2152594" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2688995" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Nasal calcitonin for treatment of established osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1846873" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2410171" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3262626" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7750020" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10996576" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6423929" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Long-term calcitonin therapy in postmenopausal osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1616360" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3079649" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21660557" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1818759" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1933618" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Use of calcitonin in the treatment of bone pain associated with osteoporosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10617256" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9385283" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
